epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile — Competitive Intelligence Brief

epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile (epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: anthracycline antibiotic, taxane, alkylating agent, antifolate, t

phase 3 anthracycline antibiotic, taxane, alkylating agent, antifolate, thymidylate synthase inhibitor topoisomerase II, microtubules, dihydrofolate reductase, thymidylate synthase Oncology Small molecule

Target snapshot

epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile (epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile) — Sanofi. Epidoxorubicine is an anthracycline antibiotic that intercalates DNA strands, thereby inhibiting the progression of topoisomerase II and inducing apoptosis in cancer cells. Docetaxel is a taxane that stabilizes microtubules, preventing cell division and leading to cell death. Ciclophosphamide is an alkylating agent that adds an alkyl group to DNA, causing cross-linking and DNA damage. Methotrexate is an antifolate that inhibits dihydrofolate reductase, leading to a decrease in DNA synthesis and cell proliferation. Fluorouracile is a thymidylate synthase inhibitor that disrupts DNA synthesis and repair.

Comparator set

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile TARGET	epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile	Sanofi	phase 3	anthracycline antibiotic, taxane, alkylating agent, antifolate, thymidylate synthase inhibitor	topoisomerase II, microtubules, dihydrofolate reductase, thymidylate synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (anthracycline antibiotic, taxane, alkylating agent, antifolate, thymidylate synthase inhibitor class)

1. Sanofi · 1 drug in this class